The Defense Health Agency awarded Brigham & Women's Hospital Inc. $140,000 on November 1, 2026, under the Military Medical Research and Development program (CFDA 12.420) to support protease-targeted chimera-mediated degradation of the TFE3-ASPSCR1 fusion protein as targeted therapy for alveolar soft part sarcoma. Performance occurs in Boston, Massachusetts through October 31, 2028. Brigham & Women's Hospital, operating as the Department of Faulkner Pathology and a subsidiary of Partners Healthcare System Incorporated, serves as the recipient. The program supports basic, applied, and advanced biomedical research to transform health care for Service Members and the American public through innovative research and investigation of medical solutions for battlefield and clinical use.